188 related articles for article (PubMed ID: 16550361)
41. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
42. A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.
Renton KW; Crocker JF; McLellan H; Acott PD
Eur J Clin Pharmacol; 2004 Aug; 60(6):421-6. PubMed ID: 15232662
[TBL] [Abstract][Full Text] [Related]
43. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
[TBL] [Abstract][Full Text] [Related]
45. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients.
Kim JS; Aviles DH; Silverstein DM; Leblanc PL; Matti Vehaskari V
Pediatr Transplant; 2005 Apr; 9(2):162-9. PubMed ID: 15787787
[TBL] [Abstract][Full Text] [Related]
46. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
[TBL] [Abstract][Full Text] [Related]
47. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure.
Filler G; Womiloju T; Feber J; Lepage N; Christians U
Am J Transplant; 2005 Aug; 5(8):2005-10. PubMed ID: 15996252
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
[TBL] [Abstract][Full Text] [Related]
49. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial.
Wlodarczyk Z; Ostrowski M; Mourad M; Krämer BK; Abramowicz D; Oppenheimer F; Miller D; Dickinson J; Undre N
Ther Drug Monit; 2012 Apr; 34(2):143-7. PubMed ID: 22406656
[TBL] [Abstract][Full Text] [Related]
50. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
51. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
Bechstein WO; Paczek L; Wramner L; Squifflet JP; Zygmunt AJ;
Transplant Proc; 2013; 45(6):2133-40. PubMed ID: 23953523
[TBL] [Abstract][Full Text] [Related]
52. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
Pape L; Ehrich JH; Offner G
Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
[TBL] [Abstract][Full Text] [Related]
53. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data.
Ben Fredj N; Woillard JB; Debord J; Chaabane A; Boughattas N; Marquet P; Saint-Marcoux F; Aouam K
Exp Clin Transplant; 2016 Aug; 14(4):394-400. PubMed ID: 27506258
[TBL] [Abstract][Full Text] [Related]
54. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
[TBL] [Abstract][Full Text] [Related]
55. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients.
Vadcharavivad S; Susomboon T; Kulabusaya B; Avihingsanon Y; Praditpornsilpa K; Townamchai N
Ther Drug Monit; 2016 Oct; 38(5):614-20. PubMed ID: 27328329
[TBL] [Abstract][Full Text] [Related]
56. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
Sobiak J; Resztak M; Głyda M; Szczepaniak P; Chrzanowska M
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):331-8. PubMed ID: 25663618
[TBL] [Abstract][Full Text] [Related]
58. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
59. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
60. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
